Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Individuals 18 - 50 years of age inclusive at the time of consent.~2. Able to read the written informed consent, states willingness to comply with all study procedures, and is anticipated to be available for all study visits.~3. Agreement to adhere to Lifestyle Considerations during the study.~4. Females of reproductive potential who have sexual intercourse with males must agree to use highly effective contraception for at least 1 month prior to signing ICF and through Day 57.~5. In good general health as evidenced by medical history, physical examination, and clinical judgement of the investigator to be in stable state of health.~   \*Participants with pre-existing stable chronic medical conditions defined as conditions not requiring significant change in therapy or hospitalization for worsening disease in the 4 weeks prior to enrollment can be included at the discretion of the investigator. This includes stable, well-controlled HIV positive individuals.~6. If HIV infected individual, they must be on suppressive Antiretroviral therapy (ART) for at least 6 months, report a cluster of differentiation 4 (CD4) count of greater than 350 cells/uL and no Acquired Immune Deficiency Syndrome (AIDS)-defining illness in the last year.~Exclusion Criteria:~1. Ever received a licensed or an investigational smallpox or monkeypox vaccine.~   \*This includes Dryvax, Acam2000, LC 16 m8, Modified Vaccinia Ankara (MVA)-based vaccine candidate or licensed vaccines, and Jynneos, Imvamune or Imvanex).~2. Any history of monkeypox, cowpox, or vaccinia infection.~3. Close contact of anyone known to have monkeypox in the 3 weeks prior to signing Informed Consent Form (ICF).~4. Immunocompromised as determined by the investigator.~5. Recent or current use of any immunosuppressing medications in the 4 weeks prior to signing ICF.~   \*\*Topical, ophthalmic, inhaled, intranasal and intraarticular corticosteroids are acceptable, but receipt of \>/= 20 mg/day of prednisone or equivalent for \>/= 14 consecutive days in the 4 weeks prior to signing ICF is exclusionary.~6. Pregnant or breast feeding.~7. Received or plans to receive a live vaccine in the 4 weeks prior to signing ICF and 4 weeks after each vaccination.~8. Received or plans to receive any other vaccine in the 2 weeks prior to signing ICF through Day 43.~9. Received experimental therapeutic agent or vaccine in the 3 months prior to signing ICF.~10. Has known allergy or history of anaphylaxis or other serious adverse reaction to a vaccine or vaccine products.~    \*\*\*This includes individuals with history of severe allergic reaction to gentamicin, ciprofloxacin, chicken or egg protein.~11. Has tattoos, scars, or other marks which would, in the opinion of the investigator, interfere with assessment of the vaccination site.~12. Has any medical disease or condition that, in the opinion of the participating site Principal Investigator (PI) or appropriate sub-investigator, precludes study participation.~    * This includes acute, subacute, intermittent, or chronic medical disease or condition that would place the participant at an unacceptable risk of injury, render the participant unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the participant's successful completion of this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): 0.1 mL of 2 x 10\^7 (50% Tissue Culture Infectious Dose (TCID50) JYNNEOS (Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN)) administered intradermally on Days 1 and 29. N=70
- Arm 2 (Type: EXPERIMENTAL): 0.05 mL of 1 x 10\^7 (50% Tissue Culture Infectious Dose (TCID50) JYNNEOS (Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN)) administered intradermally on Days 1 and 29. N=70
- Arm 3 (Type: ACTIVE_COMPARATOR): 0.5 mL of 1 x 10\^8 (50% Tissue Culture Infectious Dose (TCID50) JYNNEOS (Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN)) administered subcutaneously on Days 1 and 29. N=70

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete